ELUTIA INC (ELUT)
(Delayed Data from NSDQ)
$3.19 USD
-0.01 (-0.31%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $3.16 -0.03 (-0.94%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELUT 3.19 -0.01(-0.31%)
Will ELUT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ELUT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELUT
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
ELUT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights BRC, Costamare and Elutia
3 Best Breakout Stocks Worth a Buy for Attractive Returns
Elutia Inc. (ELUT) Upgraded to Buy: Here's Why
Other News for ELUT
SWK Holdings Provides Portfolio Update
SILVERARC CAPITAL MANAGEMENT, LLC Acquires Shares in Elutia Inc
Lake Street Sticks to Their Buy Rating for Aziyo Biologics (ELUT)
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro?, Company?s Antibiotic-Eluting BioEnvelope for Implantable Devices
Elutia announces new peer reviewed publication on EluPro